Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Ceftazidime-avibactam was used to treat 77 patients with carbapenem-resistant Enterobacteriaceae (CRE) infections at our center. Thirty- and 90-day survival rates were 81% and 69%, respectively; these rates were higher than those predicted by SAPS II and SOFA scores at the onset of infection. Clinic...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Antimicrob Agents Chemother
Päätekijät: Shields, Ryan K., Nguyen, M. Hong, Chen, Liang, Press, Ellen G., Kreiswirth, Barry N., Clancy, Cornelius J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2018
Aiheet:
Clinical Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5923134/
https://ncbi.nlm.nih.gov/pubmed/29507064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02497-17
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia